Showing 21-30 of 1716 results for "".
- Skin Cancer Foundation Champions for Change Gala Coming in Octoberhttps://practicaldermatology.com/news/skin-cancer-foundation-champions-for-change-gala-coming-in-october/2460142/The Skin Cancer Foundation’s annual Champions for Change Gala comes to The Plaza New York City October 17. The Champions for Change Gala is the signature fundraising event for The Skin Cancer Foundation’s programs and initiatives. Awards a
- Save the Date: Skin Cancer Foundation's Champions for Change Gala this Octoberhttps://practicaldermatology.com/news/save-the-date-skin-cancer-foundations-champions-for-change-gala-this-october/2457692/The Skin Cancer Foundation’s signature fundraising event, the Champions for Change Gala, is coming October 25 in New York City. Robert J. Friedman, MD will be honored as the 2019 Champion for Change. The Skin Cancer Foun
- Provectus Biopharmaceuticals Announces Leadership Changeshttps://practicaldermatology.com/news/provectus-biopharmaceuticals-announces-leadership-changes/2458674/Provectus Biopharmaceuticals, Inc. detailed several leadership changes following the resignation of one of its Co-Founders and its Chairman and CEO, H. Craig Dees, PhD. The Provectus Board of Directors accepted the resignation of Dr. Dees, which he submitted due to personal and health reasons, in
- MELA Sciences Changing Name to STRATA Skin Sciences to Reflect Broader Dermatology Commitmenthttps://practicaldermatology.com/news/mela-sciences-changing-name-to-strata-skin-sciences-to-reflect-broader-dermatology-commitment/2458771/MELA Sciences, Inc. will be changing its corporate name to STRATA Skin Sciences, Inc. effective Tuesday, January 5, 2016 and it will trade under the symbol “SSKN” on the Nasdaq Stock Market. Michael R. Stewart, President and Chief Executive Officer stated: “Our June 2015
- Syneron Candela Launches "Changing Lives" Program At AADhttps://practicaldermatology.com/news/syneron-candela-launches-changing-lives-program-at-aad/2458985/Syneron Medical Ltd. is introducing the Changing Lives Program, a corporate wide initiative that the company says leverages its life-changing technologies with life-changing causes. Launching at the annual American Academy of Dermatology (AAD) meeting in San Francisco on March 21, Changing Lives&
- Lithera Changes Name to Neothetics, Inc.https://practicaldermatology.com/news/20140812-lithera_changes_name_to_neothetics_inc/2459146/In a move the company says is intended to stregthen its positioning as a clinical stage, specialty pharmaceutical company developing novel therapeutics for the aesthetics market, Lithera has changed its name to Neothetics, Inc. President and CEO of Neothetics George Mahaffey said, "Our ne
- Cherry Angiomas Linked to NF1-Related Vascular Changes: Studyhttps://practicaldermatology.com/news/cherry-angiomas-linked-to-nf1-related-vascular-changes-study/2488158/Cherry angiomas may be a previously underrecognized vascular manifestation of neurofibromatosis type 1 (NF1), according to findings from a prospective comparative study in JAMA Dermatology. Investigators evaluated 259 participants (102 individuals with confirmed NF1 and 157 contro
- From SCALE 2026: Practical Strategies for Treating GLP-1–Related Aesthetic Changeshttps://practicaldermatology.com/news/from-scale-2026-practical-strategies-for-treating-glp-1related-aesthetic-changes/2487118/At the 2026 Music City SCALE meeting, Terrence Keaney, MD, discussed how dermatologists can proactively address facial aging, skin laxity, hair loss, and muscle loss associated with GLP-1–mediated weight reduction, outlining a practical framework for managing some of the aesthetic issues related
- Cannabis Use Linked to Lower BCC Risk, No Change in Melanoma or cSCC: Studyhttps://practicaldermatology.com/news/cannabis-use-linked-to-lower-bcc-risk-no-change-in-melanoma-or-cscc/2486395/Cannabis use was linked with decreased incidince of basal cell carcinoma (BCC), but not cutaneous squamous cell carcinoma (cSCC) or malignant melanoma (MM), according to results from a newly presented poster. Researchers for t
- New Baricitinib AA Data for Adolescents Could Be 'Game-Changing'https://practicaldermatology.com/news/New-Baricitinib-AA-Data-Adolescents-Could-Be-Game-Changing/2471600/Patients ages 12 to under 18 with severe alopecia areata (AA) treated with once-daily, oral baricitinib 4 mg and 2 mg saw clinically meaningful improvements in hair regrowth on the scalp, eyebrows, and eyelashes at Week 36 in the Phase 3 BRAVE-AA-PEDS study, presented as a late-breaker at the 202